{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:36:09Z","timestamp":1780677369982,"version":"3.54.1"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","award":["N029402"],"award-info":[{"award-number":["N029402"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UM | Rogel Cancer Center, University of Michigan","award":["F049977"],"award-info":[{"award-number":["F049977"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["T32-CA140044"],"award-info":[{"award-number":["T32-CA140044"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["T32-CA009676"],"award-info":[{"award-number":["T32-CA009676"]}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32-GM007767"],"award-info":[{"award-number":["T32-GM007767"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Cancer Institute","award":["F31-CA254138"],"award-info":[{"award-number":["F31-CA254138"]}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32-GM113900"],"award-info":[{"award-number":["T32-GM113900"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32-GM007315"],"award-info":[{"award-number":["T32-GM007315"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["T32-GM007863"],"award-info":[{"award-number":["T32-GM007863"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,20]]},"abstract":"<jats:p>Patients with radioresistant breast cancers, including a large percentage of women with triple-negative breast cancer (TNBC), demonstrate limited response to radiation and increased locoregional recurrence; thus, strategies to increase the efficacy of radiation in TNBC are critically needed. We demonstrate that pan Bcl-2 family inhibition [ABT-263, radiation enhancement ratio (rER): 1.52\u20131.56] or Bcl-xL\u2013specific inhibition (WEHI-539, A-1331852; rER: 1.31\u20132.00) radiosensitized wild-type PIK3CA\/PTEN TNBC (MDA-MB-231, CAL-120) but failed to radiosensitize PIK3CA\/PTEN-mutant TNBC (rER: 0.90\u20131.07; MDA-MB-468, CAL-51, SUM-159). Specific inhibition of Bcl-2 or Mcl-1 did not induce radiosensitization, regardless of PIK3CA\/PTEN status (rER: 0.95\u20131.07). In wild-type PIK3CA\/PTEN TNBC, pan Bcl-2 family inhibition or Bcl-xL\u2013specific inhibition with radiation led to increased levels of apoptosis (P &amp;lt; 0.001) and an increase in cleaved PARP and cleaved caspase 3. CRISPR-mediated PTEN knockout in wild-type PIK3CA\/PTEN MDA-MB-231 and CAL-120 cells induced expression of pAKT\/Akt and Mcl-1 and abolished Bcl-xL inhibitor\u2013mediated radiosensitization (rER: 0.94\u20131.07). Similarly, Mcl-1 overexpression abolished radiosensitization in MDA-MB-231 and CAL-120 cells (rER: 1.02\u20131.04) but transient MCL1 knockdown in CAL-51 cells promoted Bcl-xL inhibitor\u2013mediated radiosensitization (rER: 2.35 \u00b1 0.05). In vivo, ABT-263 or A-1331852 in combination with radiation decreased tumor growth and increased tumor-tripling time (P &amp;lt; 0.0001) in PIK3CA\/PTEN wild-type TNBC cell line and patient-derived xenografts. Collectively, this study provides the preclinical rationale for early-phase clinical trials testing the safety, tolerability, and efficacy of Bcl-xL inhibition and radiation in women with wild-type PIK3CA\/PTEN wild-type TNBC at high risk for recurrence.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study proposes a novel strategy for the treatment of radioresistant TNBCs using FDA-approved compounds that target apoptosis to improve local disease control in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0024","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T10:28:01Z","timestamp":1656498481000},"page":"679-693","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bcl-xL Inhibition Radiosensitizes\n                    <i>PIK3CA\/PTEN<\/i>\n                    Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-8792","authenticated-orcid":true,"given":"Andrea M.","family":"Pesch","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, University of Michigan, Ann Arbor, Michigan."},{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-9468","authenticated-orcid":true,"given":"Benjamin C.","family":"Chandler","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-287X","authenticated-orcid":true,"given":"Anna R.","family":"Michmerhuizen","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."},{"name":"4Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4758-1178","authenticated-orcid":true,"given":"Hannah M.","family":"Carter","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4729-5013","authenticated-orcid":true,"given":"Nicole H.","family":"Hirsh","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-1508","authenticated-orcid":true,"given":"Kari","family":"Wilder-Romans","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8522-6150","authenticated-orcid":true,"given":"Meilan","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Ward","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra L.","family":"Ritter","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-1568","authenticated-orcid":true,"given":"Charles A.","family":"Nino","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."},{"name":"4Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-8455","authenticated-orcid":true,"given":"Kassidy M.","family":"Jungles","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, University of Michigan, Ann Arbor, Michigan."},{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-5710","authenticated-orcid":true,"given":"Lori J.","family":"Pierce","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Rae","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."},{"name":"5Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-2860","authenticated-orcid":true,"given":"Corey W.","family":"Speers","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."},{"name":"3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2017.08.025","article-title":"Breast cancer biology: clinical implications for breast radiation therapy","volume":"100","author":"Horton","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","article-title":"Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group","volume":"26","author":"Kyndi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0360-3016(91)90094-K","article-title":"Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin","volume":"20","author":"Skov","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.10-1-34","article-title":"Combined modality therapy of gemcitabine and radiation","volume":"10","author":"Pauwels","year":"2005","journal-title":"Oncologist"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-019-6121-3","article-title":"Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib","volume":"19","author":"De Haan","year":"2019","journal-title":"BMC Cancer"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(86)90004-8","article-title":"Genetic control of programmed cell death in the nematode C. elegans","volume":"44","author":"Ellis","year":"1986","journal-title":"Cell"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","article-title":"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death","volume":"74","author":"Oltval","year":"1993","journal-title":"Cell"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/emboj\/17.2.384","article-title":"Bim: a novel member of the Bcl-2 family that promotes apoptosis","volume":"17","author":"O'connor","year":"1998","journal-title":"EMBO J"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cdd.2011.158","article-title":"BCL2A1: the underdog in the BCL2 family","volume":"19","author":"Vogler","year":"2012","journal-title":"Cell Death Differ"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","article-title":"Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked","volume":"275","author":"Yang","year":"1997","journal-title":"Science"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","article-title":"The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis","volume":"275","author":"Kluck","year":"1997","journal-title":"Science"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.cdd.4401908","article-title":"Dissecting p53-dependent apoptosis","volume":"13","author":"Chipuk","year":"2006","journal-title":"Cell Death Differ"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1073\/pnas.94.18.9679","article-title":"p53-independent apoptosis induced by paclitaxel through an indirect\u2009mechanism","volume":"94","author":"Lanni","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1101\/gad.14.16.2060","article-title":"tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c","volume":"14","author":"Wei","year":"2000","journal-title":"Genes Dev"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1093\/emboj\/17.14.3878","article-title":"Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis","volume":"17","author":"Gross","year":"1998","journal-title":"EMBO J"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"369ra175","DOI":"10.1126\/scitranslmed.aae0348","article-title":"PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation","volume":"8","author":"Anderson","year":"2016","journal-title":"Sci Trans Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2014.03.001","article-title":"PI3K\/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced","volume":"348","author":"Jebahi","year":"2014","journal-title":"Cancer Lett"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2018.1778","article-title":"Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1\u201398 randomized clinical trial","volume":"4","author":"Luen","year":"2018","journal-title":"JAMA Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fcell.2020.00041","article-title":"Molecular mechanisms of radiation-induced cancer cell death: a primer","volume":"8","author":"Sia","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins","volume":"51","author":"Park","year":"2008","journal-title":"J Med Chem"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"eaam7049","DOI":"10.1126\/scitranslmed.aam7049","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","volume":"9","author":"Merino","year":"2017","journal-title":"Sci Trans Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1073\/pnas.1104778108","article-title":"Sensitization of BCL-2\u2013expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737","volume":"109","author":"Oakes","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1667\/RR13856.1","article-title":"Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1","volume":"182","author":"Wu","year":"2014","journal-title":"Radiat Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-017-0038-2","article-title":"Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer","volume":"3","author":"Speers","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1002\/cncr.26003","article-title":"Prognostic web-based models for stage II and III colon cancer: a population and clinical trials-based validation of numeracy and adjuvant! online","volume":"117","author":"Gill","year":"2011","journal-title":"Cancer"},{"key":"2023031315305101400_","first-page":"2190","article-title":"Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth","volume":"60","author":"Yokoyama","year":"2000","journal-title":"Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-04-0870","article-title":"Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225)","volume":"10","author":"Matar","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"Van De Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41388-018-0436-4","article-title":"Mouse ER+\/PIK3CA H1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents","volume":"38","author":"Stratikopoulos","year":"2019","journal-title":"Oncogene"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tiv.2017.09.023","article-title":"Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin","volume":"46","author":"Lee","year":"2018","journal-title":"Toxicol In Vitro"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nchembio.1246","article-title":"Structure-guided design of a selective BCL-xL inhibitor","volume":"9","author":"Lessene","year":"2013","journal-title":"Nat Chem Biol"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-017-0169-2","article-title":"Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/ol.2017.6211","article-title":"Bcl-2\/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death","volume":"14","author":"Kasai","year":"2017","journal-title":"Oncol Lett"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"45088","DOI":"10.18632\/oncotarget.15125","article-title":"Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells","volume":"8","author":"Panayotopoulou","year":"2017","journal-title":"Oncotarget"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","article-title":"BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer","volume":"27","author":"Shahbandi","year":"2020","journal-title":"Cell Death Differ"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Transl Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-13-98","article-title":"The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells","volume":"13","author":"Wang","year":"2014","journal-title":"Mol Cancer"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-07-2183","article-title":"Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells","volume":"7","author":"Wang","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1158\/0008-5472.CAN-19-0950","article-title":"Mcl-1 interacts with Akt to promote lung cancer progression","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2012-08-447441","article-title":"Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription","volume":"122","author":"Thomas","year":"2013","journal-title":"Blood"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1158\/0008-5472.CAN-21-1208","article-title":"Cell line-specific network models of ER+ breast cancer identify potential PI3K\u03b1 inhibitor resistance mechanisms and drug combinations","volume":"81","author":"G\u00f3mez Tejeda Za\u00f1udo","year":"2021","journal-title":"Cancer Res"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.18632\/oncotarget.27070","article-title":"Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers","volume":"10","author":"Williams","year":"2019","journal-title":"Oncotarget"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"100487","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-015-0203-x","article-title":"Next-generation sequencing to guide cancer therapy","volume":"7","author":"Gagan","year":"2015","journal-title":"Genome Med"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct functions of AKT isoforms in breast cancer: a comprehensive review","volume":"17","author":"Hinz","year":"2019","journal-title":"Cell Commun Signal"},{"key":"2023031315305101400_","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2012.88","article-title":"Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Billard","year":"2012","journal-title":"Leukemia"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0024\/3166132\/crc-22-0024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/7\/679\/3282468\/crc-22-0024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/7\/679\/3282468\/crc-22-0024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:17:28Z","timestamp":1700759848000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/7\/679\/707059\/Bcl-xL-Inhibition-Radiosensitizes-PIK3CA-PTEN-Wild"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,20]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0024","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550881","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545201","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550881.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545201.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]}}}